Anti-Amyloid Drugs
The drugs cost about $28,000 per year. The drugs received accelerated FDA approval despite no clinically meaningful improvement in Alzheimer's symptoms, according to the article. Aducanumab and lecanemab are monoclonal antibodies that redu…
1 sources - 5 claims
The drugs cost about $28,000 per year. The drugs received accelerated FDA approval despite no clinically meaningful improvement in Alzheimer's symptoms, according to the article. Aducanumab and lecanemab are monoclonal antibodies that reduce amyloid plaques. The article lists brain swelling, brain bleeding, and death in some patients as side effects of anti-amyloid drugs. A meta-analysis is described as finding that these drugs increase the speed of brain atrophy.